AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00473694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrrolate
Description: Administered as an IV infusion
Study NCT01546129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dianatal Obstetric Gel (Cross-linked polyacrylic acid)
Description: Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
Study NCT03206658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Description: A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
Study NCT03206658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
Study NCT05928143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
Study NCT05928143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy
Description: Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
Study NCT04153630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells derived from bone marrow (BM-MSCs)
Description: Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
Study NCT03932955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC-19PD1 CAR-T cells
Description: T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
Study NCT03993509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the right dlPFC
Description: A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
Study NCT01157169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 8 mg Sublingual Tablets
Study NCT01157169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: 8 mg Sublingual Tablets
Study NCT00981435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 1%
Description: Prednisolone 1% to lasered eye 4 times/day for 4.5 days
Study NCT00981435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
Study NCT00981435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Description: Artificial saline tears to lasered eye 4 times/day for 4.5 days
Study NCT01351662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Self Management Program
Description: Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
Study NCT03016234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
Study NCT03016234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
Study NCT00839163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Study NCT00839163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Study NCT00839163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Study NCT00839163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Study NCT00839163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin/Vitamin K-Antagonist
Description: Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
Study NCT05598086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: local infiltration of TXA or normal saline in the post-operation would
Study NCT05598086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: local infiltration of TXA or normal saline in the post-operation would
Study NCT00929292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modilac Dahlia 1
Description: Infant formula used for non breastfed children with colic
Study NCT00929292 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Modilac 1
Description: Infant formula used for non breastfed children
Study NCT01981187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
Study NCT03843580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optiflow
Description: we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Transplantation of previously harvested peripheral blood stem cells.
Study NCT01857934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell infusion
Description: Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
Study NCT01857934 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
Study NCT03486236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440
Description: VX-440 was administered in TC with TEZ and IVA.
Study NCT01857934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given subcutaneously (SQ)
Study NCT01857934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given subcutaneously (SQ)
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Given IV
Study NCT01857934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin-2
Description: Given by continuous infusion during MRD maintenance, and SQ during induction.
Study NCT01857934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally (PO)
Study NCT01857934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT02361905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle and up to three months later
Study NCT02361905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
Study NCT02220647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Study NCT03997201 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ripple Mapping guided ischaemic VT ablation
Description: Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue.
Study NCT01460771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS (Transcranial Direct-current Stimulation)
Description: active TDCS
Study NCT01460771 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TDCS (Transcranial Direct-current Stimulation)
Description: TDCS at 0mA
Study NCT02220647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study NCT02220647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT03505463 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques.
Study NCT03505463 — intervention group
Intervention type: OTHER
Intervention: Cerebrospinal fluid sample
Description: Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques.
Study NCT03505463 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Description: Clinical examinations will be performed at \<72 hours, 7 days and 365 days post-injury.
Study NCT00541775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
Study NCT00541775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Rosiglitazone
Description: Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
Study NCT00541775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
Study NCT01815320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CE-US)
Study NCT00541775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Metformin
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
Study NCT01815320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoVue
Study NCT00541775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Metformin
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
Study NCT02291250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrants with polycal OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study NCT00541775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Metformin
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
Study NCT02291250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greencurrants with polycal OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study NCT02291250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrants with glucose OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study NCT03853200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMix Root Canal Irrigant
Description: Endodontic irrigant recommended for final irrigation
Study NCT03853200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17%EDTA+2%Chlorhexidine
Description: two endodontic irrigants will be used in this group in a sequential manner
Study NCT03853200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDTA
Description: 17% EDTA irrigation solution
Study NCT03945110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAluRil® intravesical instillations
Description: 50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
Study NCT02939781 — intervention group
Intervention type: DEVICE
Intervention: Indirect calorimetry
Description: Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
Study NCT01915147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXN PR followed by OxyPR tablets
Study NCT01915147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyPR followed by OXN PR tablets
Study NCT01645332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DLBS3233
Description: Placebo of DLBS3233 once daily for 12 weeks
Study NCT01645332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: 100 mg DLBS3233 once daily for 12 weeks
Study NCT01645332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle modification
Description: Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
Study NCT01645332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
Study NCT03109197 — intervention group
Intervention type: OTHER
Intervention: Biospecimin Collection
Study NCT02723279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPNS
Description: Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
Study NCT02723279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT
Description: Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
Study NCT02862275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02862275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT02862275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection